Antibodies targeting ADAM17 reverse neurite outgrowth inhibition by myelin-associated inhibitors., PMID:40132887
Antibodies targeting ADAM17 reverse neurite outgrowth inhibition by myelin-associated inhibitors., PMID:40132887
Anti-LINGO-1 treatment restores myelination of corticospinal tract neurons and improves functional recovery after stroke., PMID:38946137
Antagonizing LINGO-1 reduces activated microglia and alleviates dendritic spine loss in the hippocampus of APP/PS1 transgenic mice., PMID:38142924
Antagonizing LINGO-1 reduces activated microglia and alleviates dendritic spine loss in the hippocampus of APP/PS1 transgenic mice., PMID:38142924
Anti-LINGO-1 antibody protects neurons and synapses in the medial prefrontal cortex of APP/PS1 transgenic mice., PMID:36804877
Anti-inflammatory mechanisms and pharmacological actions of phycocyanobilin in a mouse model of experimental autoimmune encephalomyelitis: A therapeutic promise for multiple sclerosis., PMID:36405721
Anti-LINGO-1 antibody treatment alleviates cognitive deficits and promotes maturation of oligodendrocytes in the hippocampus of APP/PS1 mice., PMID:35014704
Anti-LINGO-1 antibody treatment alleviates cognitive deficits and promotes maturation of oligodendrocytes in the hippocampus of APP/PS1 mice., PMID:35014704
Anti-LINGO-1 improved remyelination and neurobehavioral deficit in cuprizone-induced demyelination., PMID:34712419
Anti-LINGO-1 improved remyelination and neurobehavioral deficit in cuprizone-induced demyelination., PMID:34712419
Anti-LINGO-1 antibody ameliorates cognitive impairment, promotes adult hippocampal neurogenesis, and increases the abundance of CB1R-rich CCK-GABAergic interneurons in AD mice., PMID:34044148
Anti-LINGO-1 antibody ameliorates cognitive impairment, promotes adult hippocampal neurogenesis, and increases the abundance of CB1R-rich CCK-GABAergic interneurons in AD mice., PMID:34044148
Anti-Lingo-1 antibody ameliorates spatial memory and synapse loss induced by chronic stress., PMID:32965038
Anti-Lingo-1 antibody ameliorates spatial memory and synapse loss induced by chronic stress., PMID:32965038
Nogo-A aggravates oxidative damage in oligodendrocytes., PMID:32788474
Nogo-A aggravates oxidative damage in oligodendrocytes., PMID:32788474
Anti-LINGO-1 antibody treatment improves chronic stress-induced spatial memory impairments and oligodendrocyte loss in the hippocampus., PMID:32535182
Functional activity of anti-LINGO-1 antibody opicinumab requires target engagement at a secondary binding site., PMID:31928294
Functional activity of anti-LINGO-1 antibody opicinumab requires target engagement at a secondary binding site., PMID:31928294
[Monoclonal antibodies in neurology]., PMID:31903908
[Monoclonal antibodies in neurology]., PMID:31903908
Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial., PMID:31285147
Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial., PMID:31285147
Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential., PMID:30267385
Initial Impairment and Recovery of Vision-Related Functioning in Participants With Acute Optic Neuritis From the RENEW Trial of Opicinumab., PMID:30095536
Initial Impairment and Recovery of Vision-Related Functioning in Participants With Acute Optic Neuritis From the RENEW Trial of Opicinumab., PMID:30095536
LINGO-1 antibody ameliorates myelin impairment and spatial memory deficits in the early stage of 5XFAD mice., PMID:29427384
LINGO-1 antibody ameliorates myelin impairment and spatial memory deficits in the early stage of 5XFAD mice., PMID:29427384
p75NTR and TROY: Uncharted Roles of Nogo Receptor Complex in Experimental Autoimmune Encephalomyelitis., PMID:29294247
Anti-LINGO-1 has no detectable immunomodulatory effects in preclinical and phase 1 studies., PMID:29259995
p75NTR and TROY: Uncharted Roles of Nogo Receptor Complex in Experimental Autoimmune Encephalomyelitis., PMID:29294247
Anti lingo 1 (opicinumab) a new monoclonal antibody tested in relapsing remitting multiple sclerosis., PMID:28885860
Anti lingo 1 (opicinumab) a new monoclonal antibody tested in relapsing remitting multiple sclerosis., PMID:28885860
Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial., PMID:28229892
Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial., PMID:28229892
LINGO-1 Regulates Oligodendrocyte Differentiation through the Cytoplasmic Gelsolin Signaling Pathway., PMID:28193690
LINGO-1 Regulates Oligodendrocyte Differentiation through the Cytoplasmic Gelsolin Signaling Pathway., PMID:28193690
Nogo-A Antibodies for Progressive Multiple Sclerosis., PMID:28105588
Nogo-A Antibodies for Progressive Multiple Sclerosis., PMID:28105588
LINGO-1 is a New Therapy Target and Biomarker for Ewing Sarcoma., PMID:30613826
LINGO-1 is a New Therapy Target and Biomarker for Ewing Sarcoma., PMID:30613826
Mechanisms and Medicines for Remyelination., PMID:27860545
Mechanisms and Medicines for Remyelination., PMID:27860545
Myelin injury induces axonal transport impairment but not AD-like pathology in the hippocampus of cuprizone-fed mice., PMID:27129150
Myelin injury induces axonal transport impairment but not AD-like pathology in the hippocampus of cuprizone-fed mice., PMID:27129150
Blocking LINGO-1 in vivo reduces degeneration and enhances regeneration of the optic nerve., PMID:28607723
Blocking LINGO-1 in vivo reduces degeneration and enhances regeneration of the optic nerve., PMID:28607723
Exploring the surfaceome of Ewing sarcoma identifies a new and unique therapeutic target., PMID:26979953
Exploring the surfaceome of Ewing sarcoma identifies a new and unique therapeutic target., PMID:26979953
Experimental and Clinical Advances in Immunotherapy Strategies for Spinal Cord Injury Target on MAIs and Their Receptors., PMID:26635269
Experimental and Clinical Advances in Immunotherapy Strategies for Spinal Cord Injury Target on MAIs and Their Receptors., PMID:26635269
LINGO-1 antibody ameliorates myelin impairment and spatial memory deficits in experimental autoimmune encephalomyelitis mice., PMID:26383267
LINGO-1 antibody ameliorates myelin impairment and spatial memory deficits in experimental autoimmune encephalomyelitis mice., PMID:26383267
Biogen's anti-LINGO promises nerve repair., PMID:26057957
Biogen's anti-LINGO promises nerve repair., PMID:26057957
Drug that boosts nerve signals offers hope for multiple sclerosis., PMID:25903604
Drug that boosts nerve signals offers hope for multiple sclerosis., PMID:25903604
The potential of LINGO-1 as a therapeutic target for essential tremor., PMID:25862159
The potential of LINGO-1 as a therapeutic target for essential tremor., PMID:25862159
Inhibition of LINGO-1 promotes functional recovery after experimental spinal cord demyelination., PMID:25681574
Inhibition of LINGO-1 promotes functional recovery after experimental spinal cord demyelination., PMID:25681574
Biotherapies in multiple sclerosis: a step toward remyelination and neuroprotection?, PMID:25459127
Biotherapies in multiple sclerosis: a step toward remyelination and neuroprotection?, PMID:25459127
Strategies for myelin regeneration: lessons learned from development., PMID:25221590
Strategies for myelin regeneration: lessons learned from development., PMID:25221590
Structure of the LINGO-1-anti-LINGO-1 Li81 antibody complex provides insights into the biology of LINGO-1 and the mechanism of action of the antibody therapy., PMID:24756303
Structure of the LINGO-1-anti-LINGO-1 Li81 antibody complex provides insights into the biology of LINGO-1 and the mechanism of action of the antibody therapy., PMID:24756303
Emerging injectable therapies for multiple sclerosis., PMID:24090587
Emerging injectable therapies for multiple sclerosis., PMID:24090587
Blocking LINGO-1 as a therapy to promote CNS repair: from concept to the clinic., PMID:23681979
Blocking LINGO-1 as a therapy to promote CNS repair: from concept to the clinic., PMID:23681979
Neutralization of LINGO-1 during in vitro differentiation of neural stem cells results in proliferation of immature neurons., PMID:22235341
Exposure levels of anti-LINGO-1 Li81 antibody in the central nervous system and dose-efficacy relationships in rat spinal cord remyelination models after systemic administration., PMID:21807883
Exposure levels of anti-LINGO-1 Li81 antibody in the central nervous system and dose-efficacy relationships in rat spinal cord remyelination models after systemic administration., PMID:21807883
Production of a PEGylated Fab' of the anti-LINGO-1 Li33 antibody and assessment of its biochemical and functional properties in vitro and in a rat model of remyelination., PMID:21254764
Production of a PEGylated Fab' of the anti-LINGO-1 Li33 antibody and assessment of its biochemical and functional properties in vitro and in a rat model of remyelination., PMID:21254764
Targeting the Nogo receptor complex in diseases of the central nervous system., PMID:21110803
Targeting the Nogo receptor complex in diseases of the central nervous system., PMID:21110803
LINGO-1-mediated inhibition of oligodendrocyte differentiation does not require the leucine-rich repeats and is reversed by p75(NTR) antagonists., PMID:20659559
LINGO-1-mediated inhibition of oligodendrocyte differentiation does not require the leucine-rich repeats and is reversed by p75(NTR) antagonists., PMID:20659559
Neuronal Nogo-A regulates neurite fasciculation, branching and extension in the developing nervous system., PMID:20573699
Neuronal Nogo-A regulates neurite fasciculation, branching and extension in the developing nervous system., PMID:20573699
LINGO-1 negatively regulates TrkB phosphorylation after ocular hypertension., PMID:20377621
LINGO-1 negatively regulates TrkB phosphorylation after ocular hypertension., PMID:20377621
Passive immunization with LINGO-1 polyclonal antiserum afforded neuroprotection and promoted functional recovery in a rat model of spinal cord injury., PMID:20203533
Passive immunization with LINGO-1 polyclonal antiserum afforded neuroprotection and promoted functional recovery in a rat model of spinal cord injury., PMID:20203533
Improving the solubility of anti-LINGO-1 monoclonal antibody Li33 by isotype switching and targeted mutagenesis., PMID:20198683
Improving the solubility of anti-LINGO-1 monoclonal antibody Li33 by isotype switching and targeted mutagenesis., PMID:20198683
Nogo-a regulates neural precursor migration in the embryonic mouse cortex., PMID:20093372
[Prokaryotic expression, purification of human LINGO-1(aa76-319) and preparation of its polyclonal antibody]., PMID:19923059
[Prokaryotic expression, purification of human LINGO-1(aa76-319) and preparation of its polyclonal antibody]., PMID:19923059
For research use only. Not for human or drug use.
